| 4.15 -0.01 (-0.24%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.77 | 1-year : | 6.57 |
| Resists | First : | 4.94 | Second : | 5.63 |
| Pivot price | 4.63 |
|||
| Supports | First : | 3.83 | Second : | 3.19 |
| MAs | MA(5) : | 4.24 |
MA(20) : | 4.63  |
| MA(100) : | 4.88 |
MA(250) : | 4.7 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 2.8 |
D(3) : | 3.2 |
| RSI | RSI(14): 42 |
|||
| 52-week | High : | 12.46 | Low : | 1.92 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NERV ] has closed above bottom band by 17.1%. Bollinger Bands are 5.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.38 - 4.41 | 4.41 - 4.43 |
| Low: | 4.06 - 4.09 | 4.09 - 4.12 |
| Close: | 4.1 - 4.15 | 4.15 - 4.19 |
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
Wed, 09 Sep 2026
NERV: Roluperidone's pivotal phase III trial is on track, with results expected next year and strong investor support - TradingView
Wed, 09 Sep 2026
NERV: Roluperidone's phase III trial for schizophrenia negative symptoms is on track, with results due next year - TradingView
Fri, 28 Aug 2026
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences - The Manila Times
Fri, 28 Aug 2026
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences - Yahoo Finance
Thu, 20 Aug 2026
Minerva Neurosciences (NASDAQ: NERV) COO holds 20,872 shares, 750K and 680K options - Stock Titan
Fri, 07 Aug 2026
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 93.2 (%) |
| Shares Short | 1,760 (K) |
| Shares Short P.Month | 2,420 (K) |
| EPS | -36.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -4.52 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.33 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.12 |
| PEG Ratio | 0 |
| Price to Book value | -0.92 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|